Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.

Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C, Gitelman SE, Greenbaum CJ, Gottlieb PA, Herold KC, Hessner MJ, Knip M, Jacobsen L, Krischer JP, Long SA, Lundgren M, McKinney EF, Morgan NG, Oram RA, Pastinen T, Peters MC, Petrelli A, Qian X, Redondo MJ, Roep BO, Schatz D, Skibinski D, Peakman M.

Diabetes Care. 2019 Nov 21. pii: dc190880. doi: 10.2337/dc19-0880. [Epub ahead of print]

PMID:
31753960
2.

Teplizumab in Relatives at Risk for Type 1 Diabetes. Reply.

Herold KC, Bundy BN, Krischer JP; Type 1 Diabetes TrialNet Study Group.

N Engl J Med. 2019 Nov 7;381(19):1880-1881. doi: 10.1056/NEJMc1912500. No abstract available.

PMID:
31693818
3.

Changing the landscape for type 1 diabetes: the first step to prevention.

Dayan CM, Korah M, Tatovic D, Bundy BN, Herold KC.

Lancet. 2019 Oct 5;394(10205):1286-1296. doi: 10.1016/S0140-6736(19)32127-0. Epub 2019 Sep 15. Review.

PMID:
31533907
4.

β cell responses to inflammation.

Usmani-Brown S, Perdigoto AL, Lavoie N, Clark P, Korah M, Rui J, Betancur G, Herold KC.

Mol Metab. 2019 Sep;27S:S104-S113. doi: 10.1016/j.molmet.2019.06.013. Review.

5.

Unmethylated Insulin as an Adjunctive Marker of Beta Cell Death and Progression to Type 1 Diabetes in Participants at Risk for Diabetes.

Simmons KM, Fouts A, Pyle L, Clark P, Dong F, Yu L, Usmani-Brown S, Gottlieb P, Herold KC, Steck AK; Type 1 Diabetes TrialNet Study Group.

Int J Mol Sci. 2019 Aug 8;20(16). pii: E3857. doi: 10.3390/ijms20163857.

6.

Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances.

Ahmed S, Cerosaletti K, James E, Long SA, Mannering S, Speake C, Nakayama M, Tree T, Roep BO, Herold KC, Brusko TM.

Diabetes. 2019 Jul;68(7):1366-1379. doi: 10.2337/db19-0119.

PMID:
31221801
7.

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9.

8.

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.

Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group.

Diabetes. 2019 Jun;68(6):1267-1276. doi: 10.2337/db19-0057. Epub 2019 Apr 9.

9.

Associations of HbA1c with the timing of C-peptide responses during the oral glucose tolerance test at the diagnosis of type 1 diabetes.

Ismail HM, Evans-Molina C, DiMeglio LA, Becker DJ, Libman I, Sims EK, Boulware D, Herold KC, Rafkin L, Skyler J, Cleves MA, Palmer J, Sosenko JM; Type 1 Diabetes Trial Net and Diabetes Prevention Trial-Type-1 (DPT-1) Study Groups.

Pediatr Diabetes. 2019 Jun;20(4):408-413. doi: 10.1111/pedi.12845. Epub 2019 Apr 15.

10.

Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome.

Perdigoto AL, Quandt Z, Anderson M, Herold KC.

Lancet Diabetes Endocrinol. 2019 Jun;7(6):421-423. doi: 10.1016/S2213-8587(19)30072-5. Epub 2019 Mar 15. No abstract available.

PMID:
30885563
11.

Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.

Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC; Immune Tolerance Network.

Diabetologia. 2019 Apr;62(4):655-664. doi: 10.1007/s00125-018-4786-9. Epub 2018 Dec 19.

PMID:
30569273
12.

A Call for Improved Reporting of Human Islet Characteristics in Research Articles.

Poitout V, Satin LS, Kahn SE, Stoffers DA, Marchetti P, Gannon M, Verchere CB, Herold KC, Myers MG Jr, Marshall SM.

Diabetes. 2019 Feb;68(2):239-240. doi: 10.2337/dbi18-0055. Epub 2018 Dec 14. No abstract available.

13.

A call for improved reporting of human islet characteristics in research articles.

Poitout V, Satin LS, Kahn SE, Stoffers DA, Marchetti P, Gannon M, Verchere CB, Herold KC, Myers MG Jr, Marshall SM.

Diabetologia. 2019 Feb;62(2):209-211. doi: 10.1007/s00125-018-4784-y. Epub 2018 Dec 14. No abstract available.

PMID:
30547229
14.

Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes.

Wright JJ, Salem JE, Johnson DB, Lebrun-Vignes B, Stamatouli A, Thomas JW, Herold KC, Moslehi J, Powers AC.

Diabetes Care. 2018 Dec;41(12):e150-e151. doi: 10.2337/dc18-1465. Epub 2018 Oct 10. No abstract available.

PMID:
30305348
15.

Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes.

Vecchio F, Lo Buono N, Stabilini A, Nigi L, Dufort MJ, Geyer S, Rancoita PM, Cugnata F, Mandelli A, Valle A, Leete P, Mancarella F, Linsley PS, Krogvold L, Herold KC, Elding Larsson H, Richardson SJ, Morgan NG, Dahl-Jørgensen K, Sebastiani G, Dotta F, Bosi E; DRI_Biorepository Group; Type 1 Diabetes TrialNet Study Group, Battaglia M.

JCI Insight. 2018 Sep 20;3(18). pii: 122146. doi: 10.1172/jci.insight.122146. eCollection 2018 Sep 20.

16.

Identification and Analysis of Islet Antigen-Specific CD8+ T Cells with T Cell Libraries.

Ogura H, Preston-Hurlburt P, Perdigoto AL, Amodio M, Krishnaswamy S, Clark P, Yu H, Egli D, Fouts A, Steck AK, Herold KC.

J Immunol. 2018 Sep 15;201(6):1662-1670. doi: 10.4049/jimmunol.1800267. Epub 2018 Aug 6.

17.

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.

Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group.

Diabetes Care. 2018 Sep;41(9):1917-1925. doi: 10.2337/dc18-0494. Epub 2018 Jul 16.

18.

Reprogramming human T cell function and specificity with non-viral genome targeting.

Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, Hiatt J, Saco J, Krystofinski P, Li H, Tobin V, Nguyen DN, Lee MR, Putnam AL, Ferris AL, Chen JW, Schickel JN, Pellerin L, Carmody D, Alkorta-Aranburu G, Del Gaudio D, Matsumoto H, Morell M, Mao Y, Cho M, Quadros RM, Gurumurthy CB, Smith B, Haugwitz M, Hughes SH, Weissman JS, Schumann K, Esensten JH, May AP, Ashworth A, Kupfer GM, Greeley SAW, Bacchetta R, Meffre E, Roncarolo MG, Romberg N, Herold KC, Ribas A, Leonetti MD, Marson A.

Nature. 2018 Jul;559(7714):405-409. doi: 10.1038/s41586-018-0326-5. Epub 2018 Jul 11.

19.

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.

Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC.

Diabetes. 2018 Aug;67(8):1471-1480. doi: 10.2337/dbi18-0002. Epub 2018 Jun 24. Review.

20.

Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes.

Linsley PS, Greenbaum CJ, Rosasco M, Presnell S, Herold KC, Dufort MJ.

Genes Immun. 2019 Apr;20(4):293-307. doi: 10.1038/s41435-018-0032-1. Epub 2018 Jun 21.

21.

Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience.

Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA, Herold KC, Atkinson MA.

Diabetes. 2018 Jul;67(7):1216-1225. doi: 10.2337/db18-0065. Epub 2018 May 16.

22.

Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [18F]FP-DTBZ in Healthy Subjects and Patients with Type 1 Diabetes.

Naganawa M, Lim K, Nabulsi NB, Lin SF, Labaree D, Ropchan J, Herold KC, Huang Y, Harris P, Ichise M, Cline GW, Carson RE.

Mol Imaging Biol. 2018 Oct;20(5):835-845. doi: 10.1007/s11307-018-1170-6.

23.

Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-(+)-PHNO.

Bini J, Naganawa M, Nabulsi N, Huang Y, Ropchan J, Lim K, Najafzadeh S, Herold KC, Cline GW, Carson RE.

J Nucl Med. 2018 Aug;59(8):1249-1254. doi: 10.2967/jnumed.117.197285. Epub 2018 Jan 25.

24.

MAIT Cells: A Link between Gut Integrity and Type 1 Diabetes.

Gülden E, Palm N, Herold KC.

Cell Metab. 2017 Dec 5;26(6):813-815. doi: 10.1016/j.cmet.2017.11.007.

25.

Microbiota control immune regulation in humanized mice.

Gülden E, Vudattu NK, Deng S, Preston-Hurlburt P, Mamula M, Reed JC, Mohandas S, Herold BC, Torres R, Vieira SM, Lim B, Herazo-Maya JD, Kriegel M, Goodman AL, Cotsapas C, Herold KC.

JCI Insight. 2017 Nov 2;2(21). pii: 91709. doi: 10.1172/jci.insight.91709.

26.

Oxidative Modifications in Tissue Pathology and Autoimmune Disease.

Yang ML, Doyle HA, Clarke SG, Herold KC, Mamula MJ.

Antioxid Redox Signal. 2018 Nov 10;29(14):1415-1431. doi: 10.1089/ars.2017.7382. Epub 2017 Dec 11. Review.

27.

Have we pushed the needle for treatment of Type 1 diabetes?

Naushad N, Perdigoto AL, Rui J, Herold KC.

Curr Opin Immunol. 2017 Dec;49:44-50. doi: 10.1016/j.coi.2017.09.004. Epub 2017 Oct 6. Review.

28.

Intestinal type 1 regulatory T cells migrate to periphery to suppress diabetogenic T cells and prevent diabetes development.

Yu H, Gagliani N, Ishigame H, Huber S, Zhu S, Esplugues E, Herold KC, Wen L, Flavell RA.

Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):10443-10448. doi: 10.1073/pnas.1705599114. Epub 2017 Sep 11.

29.

Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.

Long SA, Thorpe J, Herold KC, Ehlers M, Sanda S, Lim N, Linsley PS, Nepom GT, Harris KM.

Cell Immunol. 2017 Sep;319:3-9. doi: 10.1016/j.cellimm.2017.07.007. Epub 2017 Aug 18.

30.

Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice.

Ogura M, Deng S, Preston-Hurlburt P, Ogura H, Shailubhai K, Kuhn C, Weiner HL, Herold KC.

Clin Immunol. 2017 Oct;183:240-246. doi: 10.1016/j.clim.2017.07.005. Epub 2017 Jul 21.

PMID:
28739191
31.

Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.

Long SA, Thorpe J, DeBerg HA, Gersuk V, Eddy J, Harris KM, Ehlers M, Herold KC, Nepom GT, Linsley PS.

Sci Immunol. 2016 Nov;1(5). pii: eaai7793. doi: 10.1126/sciimmunol.aai7793. Epub 2016 Nov 18.

32.

β Cells that Resist Immunological Attack Develop during Progression of Autoimmune Diabetes in NOD Mice.

Rui J, Deng S, Arazi A, Perdigoto AL, Liu Z, Herold KC.

Cell Metab. 2017 Mar 7;25(3):727-738. doi: 10.1016/j.cmet.2017.01.005. Epub 2017 Feb 9.

33.

Role of Interleukin 32 in Human Immunodeficiency Virus Reactivation and Its Link to Human Immunodeficiency Virus-Herpes Simplex Virus Coinfection.

Mesquita PMM, Preston-Hurlburt P, Keller MJ, Vudattu N, Espinoza L, Altrich M, Anastos K, Herold KC, Herold BC.

J Infect Dis. 2017 Feb 15;215(4):614-622. doi: 10.1093/infdis/jiw612.

34.

Unmethylated Insulin DNA Is Elevated After Total Pancreatectomy With Islet Autotransplantation: Assessment of a Novel Beta Cell Marker.

Bellin MD, Clark P, Usmani-Brown S, Dunn TB, Beilman GJ, Chinnakotla S, Pruett TL, Ptacek P, Hering BJ, Wang Z, Gilmore T, Wilhelm JJ, Hodges JS, Moran A, Herold KC.

Am J Transplant. 2017 Apr;17(4):1112-1118. doi: 10.1111/ajt.14054. Epub 2016 Oct 24.

35.

GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis.

Beam CA, MacCallum C, Herold KC, Wherrett DK, Palmer J, Ludvigsson J; Type 1 Diabetes TrialNet Study Group.

Diabetologia. 2017 Jan;60(1):43-49. Epub 2016 Oct 4.

36.

The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus.

Durning SP, Preston-Hurlburt P, Clark PR, Xu D, Herold KC; Type 1 Diabetes TrialNet Study Group.

J Immunol. 2016 Oct 15;197(8):3076-3085. Epub 2016 Sep 21.

37.

Progress and challenges for treating Type 1 diabetes.

Garyu JW, Meffre E, Cotsapas C, Herold KC.

J Autoimmun. 2016 Jul;71:1-9. doi: 10.1016/j.jaut.2016.04.004. Epub 2016 May 17. Review.

38.

Two- and Four-Hour Tests Differ in Capture of C-Peptide Responses to a Mixed Meal in Type 1 Diabetes.

Boyle KD, Keyes-Elstein L, Ehlers MR, McNamara J, Rigby MR, Gitelman SE, Weiner LJ, Much KL, Herold KC.

Diabetes Care. 2016 Jun;39(6):e76-8. doi: 10.2337/dc15-2077. Epub 2016 Apr 13. No abstract available.

39.

Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals.

Herrin M, Tate JP, Akgün KM, Butt AA, Crothers K, Freiberg MS, Gibert CL, Leaf DA, Rimland D, Rodriguez-Barradas MC, Ruser CB, Herold KC, Justice AC.

J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):228-36. doi: 10.1097/QAI.0000000000001071.

40.

Life and death of β cells in Type 1 diabetes: A comprehensive review.

Wilcox NS, Rui J, Hebrok M, Herold KC.

J Autoimmun. 2016 Jul;71:51-8. doi: 10.1016/j.jaut.2016.02.001. Epub 2016 Mar 24. Review.

41.

Characterization of Diabetogenic CD8+ T Cells: IMMUNE THERAPY WITH METABOLIC BLOCKADE.

Garyu JW, Uduman M, Stewart A, Rui J, Deng S, Shenson J, Staron MM, Kaech SM, Kleinstein SH, Herold KC.

J Biol Chem. 2016 May 20;291(21):11230-40. doi: 10.1074/jbc.M115.713362. Epub 2016 Mar 18.

42.

Methylation of insulin DNA in response to proinflammatory cytokines during the progression of autoimmune diabetes in NOD mice.

Rui J, Deng S, Lebastchi J, Clark PL, Usmani-Brown S, Herold KC.

Diabetologia. 2016 May;59(5):1021-9. doi: 10.1007/s00125-016-3897-4. Epub 2016 Feb 24.

43.

Inducing and Administering Tregs to Treat Human Disease.

Perdigoto AL, Chatenoud L, Bluestone JA, Herold KC.

Front Immunol. 2016 Jan 22;6:654. doi: 10.3389/fimmu.2015.00654. eCollection 2015. Review.

44.

A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice.

Gill RG, Pagni PP, Kupfer T, Wasserfall CH, Deng S, Posgai A, Manenkova Y, Bel Hani A, Straub L, Bernstein P, Atkinson MA, Herold KC, von Herrath M, Staeva T, Ehlers MR, Nepom GT.

Diabetes. 2016 May;65(5):1310-6. doi: 10.2337/db15-0492. Epub 2015 Dec 30.

45.

Rituximab does not reset defective early B cell tolerance checkpoints.

Chamberlain N, Massad C, Oe T, Cantaert T, Herold KC, Meffre E.

J Clin Invest. 2016 Jan;126(1):282-7. doi: 10.1172/JCI83840. Epub 2015 Dec 7.

46.

Type 1 diabetes immunotherapy using polyclonal regulatory T cells.

Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q.

Sci Transl Med. 2015 Nov 25;7(315):315ra189. doi: 10.1126/scitranslmed.aad4134.

47.

Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells.

Hernandez AL, Kitz A, Wu C, Lowther DE, Rodriguez DM, Vudattu N, Deng S, Herold KC, Kuchroo VK, Kleinewietfeld M, Hafler DA.

J Clin Invest. 2015 Nov 2;125(11):4212-22. doi: 10.1172/JCI81151. Epub 2015 Oct 20.

48.

Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.

Tooley JE, Vudattu N, Choi J, Cotsapas C, Devine L, Raddassi K, Ehlers MR, McNamara JG, Harris KM, Kanaparthi S, Phippard D, Herold KC.

Eur J Immunol. 2016 Jan;46(1):230-41. doi: 10.1002/eji.201545708. Epub 2015 Dec 14.

49.

Endocrinology research-reflecting on the past decade and looking to the next.

Herold KC, Majzoub JA, Melmed S, Pendergrass M, Schlumberger M.

Nat Rev Endocrinol. 2015 Nov;11(11):672-80. doi: 10.1038/nrendo.2015.164. Epub 2015 Oct 13. Review.

PMID:
26460340
50.

Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.

Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2015 Oct;38(10):1975-85. doi: 10.2337/dc15-1429. Review.

Supplemental Content

Loading ...
Support Center